PTHS

Pelthos Therapeutics Inc. (PTHS) - Q1 2026 10-Q Summary

Business Context and Reporting Period

This report covers the quarterly period ended March 31, 2026. Pelthos Therapeutics Inc. is a bio-pharmaceutical company formed via a July 1, 2025 merger between Channel Therapeutics Corporation and LNHC, Inc. The company currently commercializes ZELSUVMI (berdazimer) for molluscum contagiosum and has recently acquired rights to XEPI (impetigo) and XEGLYZE (head lice), with launches expected in 2027. The company is classified as a non-accelerated filer, smaller reporting company, and emerging growth company.

Key Financial Metrics

Note: Q1 2025 figures reflect the pre-merger entity (Channel Therapeutics) which had no commercial product revenue.

Material Changes vs. Prior Period

• Revenue Generation: The company recorded $10.7 million in net product revenue from ZELSUVMI, compared to zero in the prior year, following the commercial launch in July 2025.
• Expense Surge: Operating expenses increased to $24.0 million from $1.8 million, driven by SG&A costs ($21.1 million) related to the commercial launch, sales force expansion (approx. 64 territory managers), and amortization of intangible assets ($1.0 million) from recent acquisitions.
• Financing Activity: On January 12, 2026, the company drew $30.0 million on a new $50.0 million Venture Loan and Security Agreement. Additionally, the company holds $18.0 million in Convertible Notes issued in November 2025.
• Non-Cash Gains: A $5.2 million gain was recorded from the change in fair value of convertible debt, partially offsetting the net loss. This was driven by a decline in the company's stock price and credit risk adjustments.

Guidance, Outlook, and Risks

• Liquidity: Management believes it has sufficient capital to fund operations for at least the next 12 months, citing cash on hand, forecasted ZELSUVMI sales, and the remaining $20.0 million availability on the Venture Loan facility.
• Product Pipeline: ZELSUVMI is actively being promoted. XEPI and XEGLYZE are in preparation for commercial relaunch/launch in 2027. The NaV1.7 pain program (CT2000) has dosed its first patient in a Phase 1b/2a trial.
• Risks:
  • Customer Concentration: Three wholesalers accounted for 92% of gross revenue and accounts receivable in Q1 2026.
  • Debt Covenants: The Venture Loan and Convertible Notes contain customary covenants and events of default. The Convertible Notes are secured by a lien on 10% of net sales of XEPI and Sato payments.
  • Regulatory/Political: The company is monitoring the impact of the May 2025 Executive Order regarding "Most-Favored-Nation" prescription drug pricing on international opportunities.
• Management Changes: Subsequent to the period end, Francis Knuettel II was terminated as CFO, and John M. Gay was appointed CFO, Treasurer, and Secretary effective April 10, 2026.

Investor Verification Checklist

• Revenue Quality: Verify the sustainability of ZELSUVMI sales given the high concentration (92%) among three wholesale customers.
• Debt Structure: Review the specific covenants and repayment triggers for the $30M Venture Loan and the $18M Convertible Notes, particularly the subordination and royalty pledge arrangements.
• Intangible Assets: Assess the amortization schedule and useful life assumptions for the $38.4 million in definite-lived intangible assets acquired in late 2025.
• Going Concern: Confirm that the $32M cash balance and projected cash flows are sufficient to cover the high burn rate ($13M operating cash outflow in Q1) without immediate additional dilution.
• Legal Proceedings: Monitor the status of the judgment against former CEO Christian Kopfli ($17.9M awarded) and the settlement with former CMO Dr. Eric Lang.